Physician profile
David Morris
NPI 1609879618
$750.12
in general payments reported to CMS, 2019-2025
16 companies · $36.16 in 2025
The $36.16 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $151 · 2023: $102 · 2024: $90.35 · 2025: $36.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $185.24 | 2019-2024 | Rybelsus, Wegovy |
| Amgen INC. | $94.55 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $76.26 | 2020-2024 | Mounjaro, Zepbound |
| Vanda Pharmaceuticals INC. | $55.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $53.36 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $39.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $35.05 | 2019 | |
| Glaxosmithkline, LLC. | $32.10 | 2023 | Arexvy |
| Pfizer INC. | $31.61 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $30.17 | 2019 | |
| Abbvie INC. | $27.32 | 2019 | |
| Vivus LLC | $24.86 | 2019 | |
| Abbott Laboratories | $22.58 | 2024 | Freestyle Libre |
| Amarin Pharma, INC. | $15.02 | 2019 | |
| Radius Health, INC. | $14.06 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.